Research programme: peptide-based immunotherapeutics - Bionor Holding

Drug Profile

Research programme: peptide-based immunotherapeutics - Bionor Holding

Alternative Names: Vacc CMV; Vacc Flu; Vacc HCV; Vacc HPV; Vacc-CMV (cytomegalovirus vaccine) - Bionor Holding; Vacc-Flu (universal influenza vaccine) - Bionor Holding; Vacc-HCV (hepatitis C vaccine) - Bionor Holding; Vacc-HIV; Vacc-HPV (human papillomavirus vaccine) - Bionor Holding

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionor Immuno
  • Developer Bionor Holding
  • Class Peptides; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cervical cancer; Cytomegalovirus infections; Hepatitis C; Human papillomavirus infections; Influenza virus infections

Highest Development Phases

  • Preclinical Cervical cancer; Hepatitis C; HIV infections; Human papillomavirus infections; Influenza virus infections

Most Recent Events

  • 13 Jun 2016 Preclinical development of Vacc HIV is ongoing in Norway
  • 13 Jun 2016 Preclinical trials in HIV infections in United Kingdom (Parenteral) before June 2016
  • 24 Jun 2013 Bionor Pharma receives GLOBVAC grant from the Research Council of Norway for Vacc HIV development in HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top